HCPCS Level II code J7210 identifies recombinant factor VIII (Afstyla) dosed per 1 international unit, used for treatment and prevention of bleeding in people with hemophilia A. This biologic injectable is clinically important for managing bleeding risk and maintaining hemostasis, and it represents a meaningful cost component in specialty pharmacy and outpatient infusion care.

Key national payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical purpose, typical sites of service, and the payer landscape addressed in the publication. The analysis covers reimbursement benchmarks, utilization patterns, coding and billing considerations tied to administration in outpatient infusion and office settings, and relevant policy updates affecting coverage and prior authorization practices.

The publication provides practical reference material for billing staff, revenue cycle teams, and clinicians involved in hemophilia care: a clear description of the service line, common billing modifiers and claims considerations (listed separately), and where to look for related coding guidance. Data elements not provided in the input are identified as unavailable.